XOMA (NASDAQ:XOMA) Share Price Crosses Above 200-Day Moving Average of $20.30

XOMA Co. (NASDAQ:XOMA) shares passed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $20.30 and traded as high as $26.14. XOMA shares last traded at $25.64, with a volume of 8,219 shares trading hands.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and set a $74.00 target price on shares of XOMA in a report on Friday, February 16th.

XOMA Stock Performance

The stock’s 50 day moving average is $24.69 and its two-hundred day moving average is $20.30. The stock has a market capitalization of $298.45 million, a price-to-earnings ratio of -6.35 and a beta of 0.58. The company has a current ratio of 8.68, a quick ratio of 8.68 and a debt-to-equity ratio of 1.34.

XOMA (NASDAQ:XOMA) last announced its earnings results on Friday, March 8th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.13). The firm had revenue of $1.83 million during the quarter, compared to analyst estimates of $1.01 million. XOMA had a negative net margin of 886.91% and a negative return on equity of 25.17%. Analysts expect that XOMA Co. will post -1.73 earnings per share for the current fiscal year.

Institutional Trading of XOMA

A hedge fund recently raised its stake in XOMA stock. Stonepine Capital Management LLC grew its stake in XOMA Co. (NASDAQ:XOMA) by 25.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 436,602 shares of the biotechnology company’s stock after acquiring an additional 87,203 shares during the period. XOMA accounts for approximately 2.0% of Stonepine Capital Management LLC’s holdings, making the stock its 12th largest position. Stonepine Capital Management LLC owned approximately 3.80% of XOMA worth $6,152,000 as of its most recent SEC filing. 95.92% of the stock is currently owned by hedge funds and other institutional investors.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.